Dan Vahdat, Huma CEO (Yang Guanyu/Xinhua/Alamy Live News)

With back­ing from Bay­er, a Lon­don firm will pitch its 'hos­pi­tals at home' con­cept for de­cen­tral­ized tri­als

Mon­ey is fly­ing for com­pa­nies promis­ing to rev­o­lu­tion­ize the way clin­i­cal tri­als are con­duct­ed. Leaps by Bay­er is the lat­est to get be­hind one of these play­ers, lead­ing a $200 mil­lion ven­ture round for Hu­ma Ther­a­peu­tics and its dig­i­tal “hos­pi­tal at home” tech.

Lon­don-based Hu­ma un­veiled a $130 mil­lion Se­ries C on Wednes­day, which it will use to ex­pand its dig­i­tal plat­form in the US, Asia and the Mid­dle East. As part of the round, the com­pa­ny can ex­er­cise an­oth­er $70 mil­lion com­mit­ment lat­er on.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.